Therapeutic fficacy of sitagliptin in patients with nonalcoholic fatty liver disease (NAFLD)in impaired glucose tolerance (IGT): a pilot study.
Phase 3
- Conditions
- on-alcoholic fatty liver disease
- Registration Number
- JPRN-UMIN000006197
- Lead Sponsor
- Iwasaki Naika Clinic
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
a.The criteria for exclusion from participation in the study: history of hepatic disease, such as chronic hepatitis C or concurrent active hepatitis B (serum positive for hepatitis B surface antigen), autoimmune hepatitis, primary biliary cirrhosis (PBC), sclerosing cholangitis, hemochromatosis, alpha1-antitrypsin deficiency, Wilsons disease, and current or past consumption of more than 20 g of alcohol daily. b. None of the patients had any clinical evidence of hepatic decompensation, such as hepatic encephalopathy, ascites, variceal bleeding, or elevated serum bilirubin level to more than twofold the upper limit of normal.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Before and after 6 months of sitagliptin (50mg daily) to nonalcoholic fatty liver disease (NAFLD) patients, we assessed hepatic transaminase and ultrasonographic features
- Secondary Outcome Measures
Name Time Method